This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Harvard University Expert To Host Scleroderma Webinar: New Directions For Scleroderma Treatments: Understanding The Basis For Current Clinical Trials On December 14, 2012

SAN FRANCISCO, Dec. 6, 2012 /PRNewswire-USNewswire/ -- The nonprofit Scleroderma Research Foundation (SRF) welcomes Andrew Tager, MD to present "New Directions for Scleroderma Treatments: Understanding the Basis for Current Clinical Trials " on December 14, 2012 at 11 a.m. PST. This free webinar will describe current scleroderma clinical trials and new treatments on the horizon.

Dr. Tager is Assistant Professor of Medicine at Harvard Medical School, with appointments in the Center for Immunology and Inflammatory Diseases and the Pulmonary and Critical Care Unit of the Massachusetts General Hospital (MGH). He is also Co-Director of the MGH Interstitial Lung Disease Clinic, focusing on patients with lung fibrosis, including those with scleroderma.

Dr. Tager is a clinician/scientist whose work aims to find new ways to inhibit and prevent the progression of fibrotic diseases and promote healing of scarred organs. With clinical trials currently planned that target a chemical promoting fibrosis in scleroderma skin and idiopathic pulmonary fibrosis, Dr. Tager is uniquely qualified to share how research is translating into potentially new therapeutics.

When: Friday, December 14, 2012 from 11:00 a.m.12:00 p.m. PST, including a question and answer session. The Webinar will be available for later viewing on the SRF website.

Where:Register online at www.sclerodermaRESEARCH.org.

About Scleroderma Research Foundation:The Scleroderma Research Foundation is America's leading nonprofit investor in scleroderma research. It was founded in San Francisco in 1987 by scleroderma patient Sharon Monsky who lost her battle to the disease in 2002. Monsky's legacy lives on through the organization, chaired by Luke Evnin, Ph.D., managing partner of MPM Capital, one of the world's largest dedicated investors in life sciences.

The Foundation's collaborative approach is enabling scientists from leading institutions, academia and industry to work together and develop an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs